Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. reported fourth quarter and full year 2025 results alongside business and pipeline updates. For 2025, net loss narrowed to $124.5 million, or $(0.44) per share, from $161.7 million, or $(0.69) per share, in 2024 as operating expenses declined.
Research and development expenses fell to $92.9 million from $115.4 million, while general and administrative expenses decreased to $38.6 million from $41.7 million. Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year earlier.
The company completed an upsized public offering in January 2026, raising approximately $258.8 million in gross proceeds and expects pro forma cash of $434 million to fund operations into the second half of 2028. Erasca highlighted encouraging early clinical activity for ERAS-0015, continued advancement of ERAS-4001, and new U.S. composition-of-matter patents supporting its RAS-targeting franchise, with multiple Phase 1 data readouts and trial expansions planned in 2026 and 2027.
Erasca, Inc. Chief Medical Officer Morris Shannon reported an option exercise and related share sale. On March 4, 2026, he exercised options for 20,000 shares of common stock at $1.70 per share and sold 20,000 shares in open-market transactions at a weighted-average price of $15.038 per share. These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. Following a related derivative entry dated March 4, 2025, he held 515,800 stock options, which vest monthly in 48 installments starting February 1, 2024, contingent on continued service.
Erasca Foundation filed notice under Rule 144 to sell 8,333 shares of Erasca, Inc. common stock through Merrill Lynch on or about 02/17/2026 on NASDAQ, with an aggregate market value of $99,245.03.
The foundation acquired 10,193,557 common shares as a donation from Erasca, Inc. on 07/20/2021. Over the past three months it has already sold 8,333 shares on each of 11/17/2025, 12/15/2025, and 01/15/2026, receiving gross proceeds of $21,626.50, $30,438.69, and $68,573.87 respectively.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 16,111,414 shares of Erasca Inc. common stock, representing 5.7% of the class as of 12/31/2025.
The firm reports sole power to vote and dispose of all 16,111,414 shares, with no shared voting or dispositive power. It states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Erasca.
Erasca, Inc. Chairman, CEO and 10% owner Jonathan E. Lim reported receiving a stock option grant covering 2,000,000 shares of common stock. The option has an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48 of the option shares vest each month on the 29th (or the last day of February), beginning in February 2026, so long as Lim continues to provide service to Erasca on each vesting date. After this grant, he beneficially owns options for 2,000,000 shares.
Erasca, Inc. reported insider equity activity by its CFO and CBO, David M. Chacko. On 12/15/2025, he acquired 17,793 shares of common stock at $1.1943 per share through the company’s 2021 Employee Stock Purchase Plan, bringing his directly held common shares to 279,980.
On 01/29/2026, he was granted a stock option for 640,000 shares of common stock with an exercise price of $10.31 per share. One forty-eighth of these option shares vest monthly starting in February 2026, conditioned on his continued service to Erasca.
Erasca, Inc. reported a new equity award for its Chief Medical Officer, Morris Shannon. A Form 4 shows a grant of stock options covering 625,000 shares of common stock, with an exercise price of $10.31 per share, dated January 29, 2026.
These options vest over four years: 1/48th of the shares vest each month on the 29th (or the last day of February), beginning in February 2026, as long as Shannon continues serving the company on each vesting date. All 625,000 options are reported as directly owned following this grant.
Erasca, Inc. director Michael David Varney received a stock option award reported as of January 29, 2026. The option covers 96,000 shares of common stock at an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48th of the option vests each month on the 29th day (or the last day of February), beginning in February 2026, so long as Varney continues providing service to Erasca on each vesting date.
Erasca, Inc. reported a stock option grant to its General Counsel and Corporate Secretary, Ebun Garner. The option covers 560,000 shares of Erasca common stock at an exercise price of $10.31 per share and was granted on January 29, 2026.
According to the vesting terms, 1/48th of the shares subject to the option vest monthly on the 29th of each month (or the last day of February), beginning in February 2026, as long as Garner remains in continuous service with the company. After this grant, Garner beneficially owns 560,000 stock options directly.